News
-
-
-
PRESS RELEASE
Original-Research: Cardiol Therapeutics Inc (von First Berlin Equity Research GmbH): Buy
First Berlin Equity Research reaffirms BUY recommendation with USD 7.50 price target for Cardiol Therapeutics Inc after peer-reviewed publication confirming Phase II study results in Journal of the American Heart Association (JAHA) -
-
-
-
PRESS RELEASE
Original-Research: CEL-SCI Corporation (von First Berlin Equity Research GmbH): Buy
First Berlin Equity Research provides an update on CEL-SCI Corporation, maintaining Buy rating with a revised target price of USD 15. The company's partnership with Amarox and upcoming clinical milestones are highlighted -
-
-